MammaPrint Predicts Benefit of Extended Endocrine Therapy
A secondary analysis of the IDEAL phase 3 randomized clinical trial, published in JAMA Network Open, confirms that the...
Janux Expands Phase 1b Trials for JANX007 in mCRPC
Janux Therapeutics, a clinical-stage biopharmaceutical company, announced positive interim clinical data for its JANX007 program, a Tumor Activated T...
Ajax Presents Phase 1 Trial Results of JAK2 Inhibitor for Myelofibrosis
Ajax Therapeutics announced the presentation of its ongoing first-in-human study of AJ1-11095, a next-generation Type II JAK2 inhibitor, at...
Omeros Reveals ASH Presentations
Omeros Corporation announced two upcoming presentations on their investigational MASP-3 inhibitor, zaltenibart (OMS906), at the 66th Annual Meeting of...
New Biovanta Study Shows Best Efficacy for Common Cold
The common cold carries a substantial economic burden, causing approximately $40 billion in annual productivity losses. A recent study...
Rallybio Confirmatory Study Launch in Q2 2025
Rallybio Corporation announced new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous C5 inhibitor for...
Daiichi Sankyo Oncology Progress at ESMO Asia, SABCS & ASH
Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO...
Zorevunersen Data for Dravet Syndrome at AES 2024
Stoke Therapeutics, a biotechnology company focused on RNA medicine, will present data at the 2024 American Epilepsy Society (AES)...
SUDO-550: Sudo Biosciences Doses First Participants in Phase 1 Trial of Brain-Penetrant Alloste
Sudo Biosciences, a company focused on developing precision TYK2 inhibitors, has initiated a Phase 1 clinical trial for SUDO-550....
Stem Cell Market Growth, Challenges, and Opportunities to 2028
The global induced pluripotent stem cells (iPSCs) market is poised for significant growth, projected to increase from $3.4 billion...